Flag of the European Union EU Clinical Trials Register Help

Clinical trials for multiple sclerosis

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44380   clinical trials with a EudraCT protocol, of which   7392   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    Query did not match any clinical trials.
    These are paediatric studies completed by 26 January 2007, in respect of products authorised in the Community (Article 45 of the Paediatric Regulation (EC) No 1901/2006).
    Note: Advanced search filters for country, trial phase, gender, rare disease, IMP with orphan designation in the indication and age ranges of in-utero, adult or elderly do not apply to these records.
    Study title: Glatiramer acetate treatment in patients with childhood juvenile onset multiple sclerosis - Kornek B, Bernert G, Balassy C, et al. - 2003 (Neuropediatrics 2003; 34: 120-126) Glatiramer acetate treatment in patients with childhood juvenile onset multiple sclerosis - Kornek B, Bernert G, Balassy C, et al. - 2003 (Neuropediatrics 2003; 34: 120-126)
    Active substance: GLATITRAMER
    Study summary document link (including results):
    View full study record
    Document reference: 28958
    Study title: A double−blind, placebo−controlled trial of tizanidine in the treatment of spasticity caused by multiple sclerosis. United Kingdom Tizanidine Trial Group. Neurology, Nov 1994, vol. 44, no. 11 Suppl 9, p. S70−8A double−blind, placebo−controlled trial of tizanidine in the treatment of spasticity caused by multiple sclerosis. United Kingdom Tizanidine Trial Group. Neurology, Nov 1994, vol. 44, no. 11 Suppl 9, p. S70−8
    Active substance: TIZANIDINE
    Study summary document link (including results):
    View full study record
    Document reference: 38513
    Study title: Treatments for spasticity and pain in multiple sclerosis: a systematic review.Beard S, Hunn A, Wight J. Health technology assessment (Winchester England), {Health−Technol− Assess}, 2003, vol. 7, no. 40, p. iii, ix−x, 1−111Treatments for spasticity and pain in multiple sclerosis: a systematic review.Beard S, Hunn A, Wight J. Health technology assessment (Winchester England), {Health−Technol− Assess}, 2003, vol. 7, no. 40, p. iii, ix−x, 1−111
    Active substance: TIZANIDINE
    Study summary document link (including results):
    View full study record
    Document reference: 38509
    Study title: A controlled, double-blind, clinical therapeutic, comparative study with two parallel groupd (DS 103-282 and diazepam) in ambulant/hospitalised patients with multiple sclerosis
    Active substance: TIZANIDINE
    Study summary document link (including results):
    View full study record
    Document reference: 44782
    Study title: Tizanidine treatment of spasticity caused by multiple sclerosis: results of a double−blind, placebo−controlled trial. US Tizanidine Study Group.Tizanidine treatment of spasticity caused by multiple sclerosis: results of a double−blind, placebo−controlled trial. US Tizanidine Study Group.
    Active substance: TINZANIDINE
    Study summary document link (including results):
    View full study record
    Document reference: 44795
    Study title: Treatment of spasticity with tizanidine in multiple sclerosis.Treatment of spasticity with tizanidine in multiple sclerosis.
    Active substance: TINZANIDINE
    Study summary document link (including results):
    View full study record
    Document reference: 44798
    Study title: A double−blind, placebo−controlled trial of tizanidine in the treatment of spasticity caused by multiple sclerosis. United Kingdom Tizanidine Trial Group.A double−blind, placebo−controlled trial of tizanidine in the treatment of spasticity caused by multiple sclerosis. United Kingdom Tizanidine Trial Group.
    Active substance: TINZANIDINE
    Study summary document link (including results):
    View full study record
    Document reference: 44793
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed Feb 11 17:08:15 CET 2026 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA